VIEW ALL RESEARCH-GROUP

Tumor angiogenesis group
Casanovas’ Lab

DESCRIPTION

Mechanisms of resistance to antiangiogenic therapies.
Therapeutic studies in Kidney Cancer murine models, both PDOX and syngenic.
Therapeutic studies in pancreatic NeuroEndocrine tumors.
Discovery of non-invasive biomarkers in clinical trials with antiangiogenics.

Our research group at the ProCURE Program (Catalan Institute of Oncology) and OncoBell Program (IDIBELL) is focused on determining the consequences of adaptation and resistance to anti-angiogenic cancer therapy. For that we use translational research in murine models of cancer, particularly Kindey Cancer PDOX models and NeuroEndocrine transgenic models to study in vivo mechanisms of adaptation to anti-angiogenics, and validate our findings using clinical samples from our hospital and collaborating institutions.
Our scientific achievements have been published in prestigious journals in the field of cancer research with numerous “preview”, “highlight” or commentary articles in high impact scientific journals. Furthermore, we have an important international position in the field of antitumor therapies and angiogenic resistance mechanisms.

Felix-Joan Peix

Young investigators

Laura Puigròs

Young investigators

Jessica Videira

Young investigators

Maria Del Mar Martinez Lozano

Support staff

Irene Ortiz-Rubio

Researchers

Laura Bernaus

Support staff

Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents

/in /by

Cancer Res. 2019 Oct 15;79(20):5328-5341. doi: 10.1158/0008-5472.CAN-18-3436. Epub 2019 Jun 25. ABSTRACT One of the main consequences of inhibition of neovessel growth and vessel pruning produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for […]

Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?

/in /by

Cancers (Basel). 2019 Jun 17;11(6):834. doi: 10.3390/cancers11060834. ABSTRACT Uveal melanoma is considered a rare disease but it is the most common intraocular malignancy in adults. Local treatments are effective, but the systemic recurrence rate is unacceptably high. Moreover, once metastasis have developed the prognosis is poor, with a 5-year survival rate of less than 5%, […]

Quantification of gold nanoparticle accumulation in tissue by two-photon luminescence microscopy

/in /by

Nanoscale. 2019 Jun 13;11(23):11331-11339. doi: 10.1039/c9nr01198f. ABSTRACT Nanomedicine has emerged as a promising strategy to address some of the limitations of traditional biomedical sensing, imaging and therapy modalities. Its applicability and efficacy are, in part, hindered by the difficulty in both controllably delivering nanoparticles to specific regions and accurately monitoring them in tissue. Gold nanoparticles […]

Non-invasive and quantitative in vivo monitoring of gold nanoparticle concentration and tissue hemodynamics by hybrid optical spectroscopies

/in /by

Nanoscale. 2019 Mar 21;11(12):5595-5606. doi: 10.1039/c8nr08790c. ABSTRACT Owing to their unique combination of chemical and physical properties, inorganic nanoparticles show a great deal of potential as suitable agents for early diagnostics and less invasive therapies. Yet, their translation to the clinic has been hindered, in part, by the lack of non-invasive methods to quantify their […]

Insulin-like growth factor levels and chronic lymphocytic leukaemia: results from the MCC-Spain and EpiLymph-Spain studies

/in /by

Br J Haematol. 2019 May;185(3):608-612. doi: 10.1111/bjh.15583. Epub 2018 Nov 19. NO ABSTRACT PMID:30450673 | DOI:10.1111/bjh.15583

  1. MICIU PID2022-142386OB-I00 Disección de los mecanismos de Plaquetas y genes de Coagulación en la metástasis del Cancer de Riñón Oriol Casanovas 325.000,00 €PREP2022-000672 Disección de los mecanismos de Plaquetas y genes de Coagulación en la metástasis del Cancer de Riñón Oriol Casanovas 111.758,00 €
    Proyecto PID2022-142386OB-I00 financiado por MCIU/AEI/10.13039/501100011033 y por FEDER, UE
  2. MTV3 201910-30 Identification of Kidney Cancer progression targets and biomarkers through CRISPRengineered organoids and xenograft mouse models Oriol Casanovas 136.250,00 €
  3. MICIU PID2019-107557RB-I00 Targeteando la Coagulación en la formación de metástasis en cáncer renal Oriol Casanovas 145.200,00 €
    Proyecto PID2019-107557RB-I00 financiado por MICIU/AEI /10.13039/501100011033
  4. AGAUR 2021 SGR 01289 Interacció Tumor Estroma i Resistència Terapèutica – ITERT Oriol Casanovas 40.000,00 €

    Tech Transfer Projects

  5. MICIU CPP2023-010718 Opening a New Era in Hepatocellular Carcinoma by a Novel Blood Biomarker for Individual Selection of Treatment (PersonalHCC) Oriol Casanovas 514.874,00 €
    Proyecto CPP2023-010718 financiado por MICIU/AEI/10.13039/501100011033 y por FEDER, UE.
  6. AGAUR 2022 DI 00052 Inhibiting Cannibalism to Fight Resistant Tumors Oriol Casanovas 33.960,00 €
  7. MICIU PDC2021-121308-I00 Desarrollo de un nuevo biomarcador y su ‘kit’ prototipo para predecir la Respuesta Agresiva en Cancer Oriol Casanovas 132.250,00 €
    Proyecto PDC2021-121308-I00 financiado por MCIU/AEI/10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR
  8. ISCIII DTS21/00163 Angiotheragnostics: Desarrollo de un nuevo tratamiento con su biomarcador de selección de pacientes para pacientes con cáncer colorectal avanzado. Oriol Casanovas 149.600,00 €


International:
Douglas Hanahan, ISREC

Gabriele Bergers, KULeuven

Masahiro Inoue, Univ.Osaka

Kristian Pietras, Karolinska I.

Enrico Giraudo, IRCC

Stefano Indraccolo, IOV


National:

Joan Carles, VHIO

Cristina Suárez, VHIO

Maria Ochoa, ICO

August Vidal, HUB

Ramon Salazar, ICO

X García del Muro, ICO

Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

Sureda’s & Farre’s LabGrup-Hematoligia-webViñals's labViñals’s lab